Skip to main content
Premium Trial:

Request an Annual Quote

One Patent, Six Patent Applications Related to RNAi Published by USPTO

Premium

Title: Methods for Synthesizing Nucleosides, Nucleoside Derivatives, and Non-Nucleoside Derivatives. Number: 6,686,463. Filed: Aug. 31, 2001. Granted: Feb. 3, 2004. Lead Inventor: Leonid Beigelman, Sirna Therapeutics.

This patent, its abstract states, covers an invention providing “methods for the chemical synthesis of nucleosides and derivatives thereof, including 2’-amino, 2’-N-phthaloyl, 2’-O-methyl, 2’-O-silyl, 2’-OH nucleosides, C-nucleosides, nucleoside phosphoramidites, C-nucleoside phosphoramidites, and non-nucleoside derivatives.”


Title: POSH Nucleic Acids, Polypeptides, and Related Methods. Number: 20040025196. Filed: Nov. 12, 2002. Lead Inventor: Iris Alroy, The Weizmann Institute of Science.

The patent application, its abstract states, “discloses novel polypeptides and nucleic acids involved in a variety of biological processes, including viral replication.”

Specifically, the application covers “a ribonucleic acid comprising between [five] and 1,000 consecutive nucleotides of a nucleic acid sequence that is at least 90 percent identical to [specific] sequence[s] … and which, when introduced into a cell, decreases the level of a POSH mRNA and/or a POSH polypeptide. This ribonucleic acid, the application notes, includes one selected from groups of siRNAs and ribozymes.

POSH, the application states, stands for “plenty of SH3 domains.”


Title: Oligonucleotide Compositions and Methods for the Modulation of the Expression of B7 Protein. Number: 20040023917. Filed: May 23, 2003. Lead Inventor: Frank Bennett, Isis Pharmaceuticals.

The patent application’s abstract states that the invention relates to “compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.”

Specifically, the application covers the delivery of an “antisense compound eight to 30 nucleobases in length targeted to a nucleic acid molecule encoding a human B7 protein.”

This antisense compound, an antisense oligo, “comprises at least one lipophilic moiety [by] which [the] oligonucleotide is aerosolized and inhaled,” the application notes, adding that the oligo may be administered intranasally, intrapulmonarily, or intrathacheally.


Title: Compositions and Methods for Modulating Bone Mineral Deposition. Number: 20040023916. Filed: April 28, 2003. Lead Inventor: Jose Luis Millan, The Burnham Institute.

According to the patent application, the invention is a “method for decreasing matrix mineralization in a tissue of a patient having insufficient or deficient ANK activity or expression, comprising administering an amount of a TNAP inhibitor to the tissue or patient effective to inhibit TNAP expression or activity.”

The patent application’s abstract notes that “the key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition.” It adds that “PC-1 is a direct antagonist of TNAP function,” and that “ANK also antagonizes TNAP-dependent matrix calcification.

The patent application specifically covers the inhibition of TNAp using an antisense agent, an siRNA, or an antibody.


Title: Bacterial BCL-2 Domain-Containing Polypeptides, Encoding Nucleic Acid Molecules, and Related Methods. Number: 20040023866. Filed: Nov. 13, 2002. Lead Inventor: Adam Godzik, The Burnham Institute.

The patent application, states its abstract, relates to an invention providing “isolated Bcl-2 domain-containing polypeptides from Mycobacterial species … including modifications of such polypeptides, functional fragments therefrom, encoding nucleic acid molecules, and specific antibodies.”

Also covered are methods for identifying “polypeptides and compounds that associate with, or modulate activity of, the Bcl-2 domain-containing polypeptides Further provided are methods of modualting apoptosis and treating pathological conditions using the described nucleic acid molecules, polypeptides, and compounds.”

The patent application specifically covers the use of antisense, dsRNA, or ribozyme nucleic acid molecules to modulate apoptosis when they specifically hybridize to a specific nucleic acid sequence disclosed.


Title: SiRNA-Mediated Gene Silencing with Viral Vectors. Number: 20040023390. Filed: May 5, 2003. Lead Inventor: Beverly Davidson, University of Iowa.

The patent application’s abstract states that the invention “is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.”

The application notes that the vector of the invention contains “an expression cassette, wherein the expression cassette comprises a pot II promoter operably linked to a nucleic acid sequence encoding a small interfering RNA molecule targeted against a gene of interest.” This siRNA, the application adds, “forms a hairpin structure comprising a duplex structure and a loop structure.”


Title: Wise/Sost Nucleic Acid Sequences and Amino Acid Sequences. Number: 20040023356. Filed: June 16, 2003. Lead Inventor: Robb Krumlauf, Stowers Institute for Medical Research.

According to the patent application’s abstract, the invention “relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP.”

The nucleic acid sequence and polypeptides include “Wise and Sost, as well as a family of molecules which express a cysteine knot polypeptide,” the abstract states. “Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, [monoclonal] antibodies, Fab fragments, and methods for impacting the pathways.”

The patent application specifically notes that the nucleic acid molecules are selected from a group consisting of genes, mRNA, cDNA, gDNA, tRNA, RNAi, [and] siRNA, among others.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.